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ABSTRACT
Objective To identify imaging markers predicting 
clinical outcomes to regorafenib in metastatic colorectal 
carcinoma (mCRC).
Methods The RadioCORRECT study is a post hoc analysis 
of a cohort of patients with mCRC treated within the 
phase III placebo-controlled CORRECT trial of regorafenib. 
Baseline and week 8 contrast-enhanced CT were used to 
assess response by RECIST 1.1, changes in the sum of 
target lesion diameters (ΔSTL), lung metastases cavitation 
and liver metastases density. Primary and secondary 
objectives were to develop ex novo univariable and 
multivariable models to predict overall survival (OS) and 
progression-free survival (PFS), respectively.
Results 202 patients were enrolled, 134 (66.3%) treated 
with regorafenib and 68 (33.7%) with placebo. In the 
univariate analysis, PFS predictors were lung metastases 
cavitation at baseline (HR 0.50, 95% CI 0.27 to 0.92, 
p=0.03) and at week 8 (HR 0.58, 95% CI 0.36 to 0.93, 
p=0.02). Baseline cavitation (HR 0.23, 95% CI 0.08 to 
0.66, p=0.007), RECIST 1.1 (HR 0.23, 95% CI 0.14 to 
0.4, p <0.0001) and ΔSTL (HR 1.16, 95% CI 1.06 to 1.27, 
p=0.002) predicted OS. We found an increase of 9% of 
diameter as the best threshold for discriminating OS (HR 
2.64, 95% CI 1.61 to 4.34, p <0.001). In the multivariate 
analysis, baseline and week 8 cavitation remained 
significant PFS predictors. Baseline cavitation, RECIST 
1.1 and ΔSTL remained predictors of OS in exploratory 
multivariable models. Assessment of liver metastases 
density did not predict clinical outcome.
Conclusions RECIST 1.1 and ΔSTL predict favourable 
outcome to regorafenib. In contrast to liver metastases 
density that failed to be a predictor, lung metastases 
Original Research
Key questions
What is already known about this subject?
 ► Presently, no molecular markers of sensitivity or 
resistance to regorafenib are validated in clinical 
practice. Since a rapidly growing body of knowledge 
suggests that tumour response to multikinase 
inhibitors may not be adequately described by 
RECIST, we investigated whether new radiological 
parameters can predict outcomes to regorafenib in 
metastatic colorectal carcinoma (mCRC).
What does this study add?
 ► The RadioCORRECT study showed that RECIST 1.1 
and change in the sum of target lesion diameters 
(ΔSTL) assessed by week 8 contrast-enhanced CT 
predict overall survival (OS) to regorafenib in mCRC. 
The evaluation of liver metastases density failed to 
predict clinical outcome, while the presence of lung 
metastases cavitation is associated with favourable 
outcome to regorafenib.
How might this impact on clinical practice?
 ► RECIST 1.1 remains an adequate method to assess 
response to regorafenib since it is associated with 
OS. The evaluation of tumour size as a continuous 
variable, expressed as ΔSTL, supports continuation 
of treatment in those patients with stable disease, 
without any tumour shrinkage. We identify lung 
metastases cavitation as a new imaging marker, 
which deserves consideration.
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cavitation represents a novel radiological marker of favourable outcome 
that deserves consideration.
INTRODUCTION
Regorafenib prolongs progression-free survival (PFS) and 
overall survival (OS) in patients with pretreated metastatic 
colorectal carcinoma (mCRC).1 2 The multikinase activity 
of regorafenib makes it difficult to identify molecular 
markers of sensitivity or resistance.3 In the era of targeted 
therapies, a rapidly growing body of knowledge has 
generated criticisms regarding timing and parameters for 
cancer response evaluation. Preliminary studies suggest 
that radiological assessment of early tumour shrinkage 
and changes in tumour density are potential predic-
tive markers to targeted agents.4–6 Regorafenib induces 
tumour shrinkage, although commonly not reaching 
partial response (PR) by RECIST. We also noticed that 
regorafenib causes reduction in tumour density of liver 
metastases and cavitation of pulmonary metastases; the 
latter appears to be associated with a reduced risk of 
progressive disease (PD).7–9 Based on these observations, 
we hypothesised that these radiological changes likely 
mirror a biological effect that parallels clinical outcome. 
Therefore, we tested whether changes in tumour char-
acteristics detected by contrast-enhanced CT (CECT) 
would be a radiological imaging marker predicting clin-
ical outcomes.
PATIENTS AND METHODS
RadioCORRECT is an investigator-initiated post hoc 
analysis of patients from the phase III placebo-controlled 
CORRECT trial (NCT 01103323), which enrolled 760 
patients with refractory mCRC randomly assigned (2:1) 
to receive regorafenib (n=505) or placebo (n=255).1 
The RadioCORRECT study was approved by the Institu-
tional Review Board at the coordinating centre (Grande 
Ospedale Metropolitano Niguarda, Milan, Italy) and 
at participating institutions, and was conducted in 
accordance with Declaration of Helsinki. Patients were 
collected from the 13 highest recruiting institutions 
(four Italy, four France, three Belgium, one Spain, one 
the USA) and were included whether they had their first 
post-treatment evaluation by CECT at week 8.
Primary and secondary objectives were to develop 
univariable and multivariable models for patients treated 
with regorafenib by testing the following early radiolog-
ical parameters for prediction of OS and PFS, respectively: 
response by RECIST 1.1 at week 8; change in the sum of 
target lesion diameters (ΔSTL) at week 8; cavitation of 
lung metastases at baseline and at week 8; tumour density 
of liver metastases at baseline and at week 8.
RADIOLOGICAL METHODS
Participating institutions provided baseline and week 8 
CECT images of the chest, abdomen and pelvis. Tumour 
response by RECIST 1.1, sum of target lesion diameters 
(STL), PFS and OS were retrieved from the CORRECT 
database. The cut-off of this data was 21 July 2011 as 
reported in the final analysis of the CORRECT trial.1 Cavi-
tation of lung metastases and tumour density of liver 
metastases were analysed at the coordinating centre by 
two experienced radiologists who were blinded to patient 
treatment and outcomes. Cavitation was assessed in a 
consensus reading session. At baseline CECT, cavitation 
was defined as the presence of an air-filled cavity ≥10% of 
the maximum diameter in one or more lung metastasis 
≥10 mm, while at week 8 CECT as de novo onset or as 
an increase of a pre-existent cavitation. Tumour density 
of liver metastases was evaluated in two separate reading 
sessions and expressed in Hounsfield units (HU) with SD 
(σ). Measurements were assessed in the portal venous 
phase by drawing a region of interest (ROI) around the 
margins of the lesions, excluding necrotic areas. These 
ROIs were then analysed by week 8 CECT to detect any 
variation in density. We considered each one of the 
lesions reported in the CORRECT trial. Tumour density 
(µ) and σ were analysed separately. When two liver metas-
tases were present, µ and σ were summarised by the mean 
value. The percentage change from baseline at week 8 
in µ (Δµ) and σ (Δσ) was calculated as follows: [(week 8 
value - baseline value) / baseline value] × 100.
STATISTICAL METHODS
The Cox regression model was the unique statistical 
tool used for the development of PFS and OS predictive 
models; the HR was used as the population parameter.10–12 
For analysis of continuous parameters, the ratio between 
week 8 and baseline values (Ra) was computed for each 
patient; the ratio between Ra for regorafenib and placebo 
(RR) was estimated by fitting a linear regression model to 
observed Ra values on a log scale. The t-statistic was used 
to test H0: log RR=0. For categorical parameters, Fisher’s 
exact test was used.
Survival functions were estimated using the Kaplan-
Meier method. Baseline covariate distributions, 
radiological parameters and clinical outcomes were 
summarised using descriptive statistics (median, IQR and 
range for continuous variables, absolute and percentage 
frequencies for categorical variables).
Sequential analytical procedures applied for predictive 
models
Step I: screening predictors
For each predictor, a main effect was mandatory; the 
Wald test statistic was used to test H0: log HR=0; all statis-
tical tests were two-sided and statistical significance was 
detected at the 5% probability level; a p-value >0.05 
stopped further research on the predictor.
Step II: assessment of model fit and development of 
univariable PFS predictive models
IIa. In order to test the linearity assumption for a contin-
uous predictor, a restricted cubic spline function was 
added to each model successfully evaluated in step I; 
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knots were defined considering the percentile distribu-
tion respectively of the predictor; Akaike’s information 
criterion (AIC) was used for a data-based choice of 
the number of knots; a formal test (refer to R function 
anova() inside the R rms package) was performed at the 
0.05 significance level to detect deviation from linearity.
IIb. In order to test graphically the proportional hazard (PH) 
assumption and to determine a functional form yielding 
linearity, the log HR function (and 95% confidence band) 
was plotted; logarithmic and polynomials were considered 
as interesting transformations; the model maximizing AIC 
was the best 'for the money'; the Grambsch-Therneau test 
was performed in order to test formally the PH assumption.
IIc. In order to identify the best thresholds for a contin-
uous predictor, the CART methodology was applied to 
each model successfully evaluated in step I; the regression 
trees were generated through the R rpart package; each 
tree was pruned back in order to avoid data overfitting; 
the tree size that minimised the cross-validated error was 
chosen; at least one threshold was mandatory.
Step III: developing multivariable predictive models
All identified predictors, time-interaction terms, non-linear 
terms and linear interactions were introduced in a full 
model; a backward elimination Cox regression procedure 
at 0.20 level was run to identify the strongest predictors.
Step IV: performance of predictive models
The discriminatory ability of the identified univariable 
and multivariable Cox regression models was assessed 
by the Harrell's C-index. Apart from backward selection, 
predictive models were developed using the R software, 
version 3.2.3. Backward selection for the multivariable 
Cox regression models was performed using the SAS soft-
ware (SAS Institute, Cary, NC, USA), version 9.2.
RESULTS
Overall, 202 patients were analysed (see online supple-
mentary figure S1). Patient characteristics are reported in 
table 1. At baseline, the STL was 91.5 mm (range 10–344) 
for regorafenib and 88 mm (range 10–237) for placebo. 
At a median follow-up of 8.8 months for regorafenib (IQR 
7.2–10.6) and 8.2 months for placebo (IQR 6.3–9.4), 
the median PFS was 3.2 months (95% CI 1.9 to 3.5, IQR 
1.8–5.5) and 1.7 months (95% CI 1.7 to 1.8, IQR 1.6–1.9), 
respectively (HR 0.43, 95% CI 0.31 to 0.59, p <0.001). 
Median OS was 9.5 months (95% CI 7.2 to 10.8, IQR 4.9–
NR) and 6.6 months (95% CI 5.4 to 7.8, IQR 3.7–NR) for 
regorafenib and placebo (HR 0.67, 95% CI 0.45 to 1.01, 
p=0.05). At the time of the analysis, PFS and OS events 
were reached in 119/134 (88.8%) and 65/134 (48.5%) 
patients in the regorafenib group and in 65/68 (95.6%) 
and 39/68 (57.3%) patients in the placebo group.
ASSESSMENT OF RADIOLOGICAL PARAMETERS IN THE 
OVERALL POPULATION
RECIST 1.1 and ΔSTL
Among the 199 patients evaluable for dimensional 
response, the disease control rate (DCR) was 53.4% 
(70/131) and 20.6% (14/68) in patients treated with 
regorafenib and placebo (p <0.001). No PR to rego-
rafenib was reported. Median ΔSTL was 4% (IQR −3.8 to 
16.4) and 21% (IQR 5.1–40.4%) in the regorafenib and 
placebo groups (RR 0.89, 95% CI 0.84 to 0.95, p <0.001), 
respectively (see online supplementary figure S2).
Cavitation of lung metastases
At baseline, cavitation was found in 18/88 (20.4%) 
and in 3/43 (6.9%) patients treated with regorafenib 
and placebo (p=0.07). Some examples of cavitation are 
displayed in figure 1. At week 8, cavitation was found 
in 36/88 (40.9%) and 0/43 (0%) patients treated with 
regorafenib and placebo, respectively (p <0.001). Overall, 
24/70 (34.3%) patients had de novo cavitation and 12/18 
(66.7%) had an increase of a pre-existing cavitation 
(p=0.002). Week 8 cavitation was associated with RECIST 
1.1 response. In the regorafenib group, DCR was 69.7% 
(23/33) and 42.3% (22/52) in patients with and without 
cavitation at week 8 (p=0.01) and 66.7% (12/18) versus 
49.2% (33/67) in patients with and without baseline cavi-
tation (p=0.29). In the subgroup with baseline cavitation, 
the DCR was 91.7% (11/12) and 16.7% (1/6) in patients 
with or without cavitation increase at week 8 (p=0.004). 
However, the small number of patients with cavitated 
metastases at baseline limits the interpretation of data. 
In the subgroup without baseline cavitation, the DCR was 
57.1% (12/21) and 45.6% (21/46) in patients with or 
without cavitation onset at week 8 (p=0.44).
Density of liver metastases
At baseline, median µ for regorafenib and placebo was 59 
HU (range 19–108) and 51 HU (range 26–92) versus 58 
HU (range 24–110) and 52 HU (range 22–88) as assessed 
by radiologists A and B, respectively. Median σ for rego-
rafenib and placebo was 17 HU (range 9–38) and 18 HU 
(range 7–27) versus 18 HU (range 9–40) and 19 HU (range 
9–30) according to radiologists A and B, respectively. At 
week 8, the Δµ for regorafenib and placebo was −33% 
(IQR −44 to −20) and −15% (IQR −21.8 to 0.3) as assessed 
by radiologist A (RR 0.79, 95% CI 0.71 to 0.88, p <0.001) 
versus −29% (IQR 41 to −19) and −12% (IQR −19 to –2) 
as assessed by radiologist B (RR 0.78, 95% CI 0.70 to 0.86, 
p <0.001). The Δσ for regorafenib and placebo was −11% 
(IQR −21 to −5) and 7% (IQR −7.1 to 32.3) according to 
radiologist A (RR 0.81, 95% CI 0.73 to 0.90, p <0.001) 
versus −11% (IQR −21 to −4) and 6% (IQR −9 to −31) 
according to radiologist B (RR 0.85, 95% CI 0.79 to 0.92, 
p <0.001). Bland-Altman plots showed good inter-ob-
server agreement (see online supplementary figure S3).
SURVIVAL IN PATIENTS TREATED WITH REGORAFENIB
Progression-free survival
Table 2 summarises the results of univariate analysis. 
RECIST response and ΔSTL were excluded from this 
analysis because they define PFS. Baseline cavitation (HR 
0.50, 95% CI 0.27 to 0.92, p=0.03; Harrell's C-index, 0.54) 
and week 8 cavitation (HR 0.58, 95% CI 0.36 to 0.93, 
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Table 1 Patient characteristics
Treatment
N (%)
Placebo Regorafenib
All cases 68 (33.7) 134 (66.3)
Age, median, years 63.6 59.6
Sex
 Male 44 (64.7) 76 (56.7)
 Female 24 (35.3) 58 (43.3)
ECOG performance status
 0 38 (55.9) 82 (61.2)
 1 30 (44.1) 52 (38.8)
KRAS status
 Wild type 25 (38) 59 (48)
 Mutated 41 (62) 65 (52)
 Missing 2 (3) 10 (7)
Previous treatment with bevacizumab
 Yes 68 (100.0) 134 (100.0)
More than three lines before randomisation
 No 36 (52.9) 57 (42.5)
 Yes 32 (47.1) 77 (57.5)
Time from M1 diagnosis to randomisation
 Median, years 2.3 2.7
 Q1 1.5 1.7
 Q3 3.8 3.8
Site of target lesions
 Liver 38 (55.9) 92 (68.7)
  Target lesions, no.
   1 14 (37.8) 30 (33.0)
   2 23 (62.2) 61 (67.0)
   Missing 1 (2.6) 1 (1.1)
 Lung 43 (63.2) 88 (65.7)
  Target lesions, no.
   1 19 (45.2) 28 (32.2)
   2 23 (54.8) 59 (67.8)
   Missing 1 (2.3) 1 (1.1)
 Other sites
  Lymphnode 8 (30.8) 20 (41.7)
  Abdominal cavity/pelvis 8 (30.8) 10 (20.8)
  Peritoneum 5 (19.2) 14 (29.2)
  Adrenal gland 4 (15.4) 2 (4.2)
  Intestine/rectum 0 (0.0) 2 (4.2)
  Other sites 11 (42.3) 11 (22.9)
ECOG, Eastern Cooperative Oncology Group.
p=0.02; Harrell's C-index, 0.57) predicted PFS. Median 
PFS was 3.5 months (95% CI 2.8 to 5.7) and 1.9 months 
(95% CI 1.8 to 3.4) in patients with and without cavitation 
at week 8 versus 3.4 months (95% CI 1.9 to 7.8) and 2 
months (95% CI 1.8 to 3.5) in those with and without 
cavitation at baseline, respectively (figure 2). In a 
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Figure 1 Baseline (A) and week 8 (B) CT displaying the 
onset of cavitation at week 8 in two patients treated with 
regorafenib. Upper: the arrow highlights single tumour 
metastases with cavitation. Lower: cavitation in multiple 
lung metastases.
multivariable model that included all radiological and 
clinical predictors identified by the univariate analysis, 
both baseline and week 8 cavitation remained significant 
predictors of PFS (see online supplementary table S1). 
An interaction analysis showed that patients with base-
line cavitation had a median PFS of 7.4 months (95% CI 
2.8 to NR) if they had an increase of cavitation at week 8 
versus 1.8 months (95% CI 1.0 to 3.4) if they did not (HR 
0.10, 95% CI 0.02 to 0.42, p=0.002; Harrell's C-index, 
0.72) (figure 2). Conversely, the PFS of patients without 
baseline cavitation was not affected by de novo onset of 
cavitation at week 8 (HR 0.96, 95% CI 0.57 to 1.63, p=0.88; 
Harrell's C-index 0.52, interaction p=0.001) (figure 2).
Overall survival
At univariate analysis, the radiological variables predicting 
OS were baseline cavitation (HR 0.23, 95% CI 0.08 to 0.66, 
p=0.007; Harrell's C-index 0.60), RECIST 1.1 (HR 0.23, 
95% CI 0.14 to 0.4, p <0.001; Harrell's C-index 0.70) and 
ΔSTL (HR 1.16, 95% CI 1.06 to 1.27, p=0.002; Harrell's 
C-index, 0.63) (table 2). By applying CART methodology, 
we found an increase of 9% of diameter in tumour size 
as the best threshold for discriminating OS. Patients with 
STL increase ≥9% had a median OS of 5.8 months (95% 
CI 4.7 to 7.3); instead patients with a variation <9% had a 
median OS of 10.8 months (95% CI 9.0 to NR) (HR 2.64, 
95% CI 1.61 to 4.34, p <0.001) (figure 3). Median OS for 
patients with and without baseline cavitation was 11.8 
(95% CI 10.8 to NR) and 8.7 months (95% CI 5.7 to 10.4), 
respectively (figure 3). The OS of patients with baseline 
cavitation was not affected by cavitation onset at week 8 
(interaction, p=0.74). Patients with DCR and PD had a 
median OS of 11.5 months (95% CI 9.8 to NR) and 5.5 
months (95% CI 4.4 to 6), respectively (figure 3). In an 
exploratory analysis, multivariable Cox models showed 
that cavitation at baseline, RECIST 1.1 and ΔSTL were 
predictors of OS (see online supplementary table S2). 
We reported the Harrell's C-index for each predictor 
statistically associated to PFS and OS. Since no compar-
ison between different predictors was planned by study 
design, we reported this discriminatory measure only with 
a descriptive purpose.
DISCUSSION
The RadioCORRECT study showed that an early radiolog-
ical evaluation of tumour response is helpful to predict 
clinical outcome to regorafenib in mCRC. We found that 
RECIST 1.1 and ΔSTL are predictors of OS. Moreover, 
our findings suggest that slowing tumour progression 
down by limiting the increase in STL to 9%, even without 
tumour shrinkage, was sufficient to predict a prolonga-
tion of OS. Since response to multikinase inhibitors may 
not be adequately described by dimensional criteria, we 
evaluated if other radiological markers could be iden-
tified, such as cavitation of lung metastases and density 
of liver metastases.5 13–16 Literature data indicate that 
cavitation in lung metastases may occur spontaneously 
or, more frequently, may be induced by cancer therapy, 
especially by anti-angiogenetic agents.17–21 It has been 
postulated that the appearance of an air-filled cavity is 
a consequence of central necrosis due to an insufficient 
blood supply after inhibition of angiogenesis or caused 
by arterial thrombosis. In 2013, we described for the first 
time the onset of cavitation of lung metastases in a small 
cohort of patients with mCRC treated with regorafenib 
and subsequently found an association with DCR.7 9 The 
present study confirms our preliminary observations. We 
hypothesise that cavitation induced by regorafenib might 
depend on its broad multikinase inhibitory activity on 
tumour microenvironment, angiogenesis and tumour 
growth. The absence of onset of cavitation in patients 
receiving placebo corroborate this remark. In patients 
treated with regorafenib, we found that the presence 
of cavitation in lung metastases at week-8 was associated 
with DCR and PFS. More than 20% of patients treated 
with regorafenib showed cavitation at baseline CECT. 
These patients are more likely to develop an increase of 
cavitation at week-8 and they achieved greater PFS and 
OS when compared with those without baseline cavita-
tion. These findings have significant implications and 
might be helpful for therapeutic choice before treatment 
begins. Our data appear in agreement with the proposal 
of other authors to consider tumour cavitation as a new 
radiological biomarker.22 23 Recently, Lim et al evaluated 
lung metastases cavitation in 53 mCRC patients treated 
with regorafenib.24 Although 32.1% of these patients 
developed cavitation, no significant association with clin-
ical outcome was reported. These results are in contrast 
with those of the present study, but the small number 
of patients may have underpowered the statistical anal-
ysis. Indeed, patients with cavitary changes showed a 
non-significant prolongation of PFS and a greater DCR 
(82.4% vs 63.9%). Furthermore, these authors analysed 
 o
n
 27 July 2018 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2016-000111 on 13 February 2017. Downloaded from
 
Open Access
6 Ricotta R, et al. ESMO Open 2017;1:e000111. doi:10.1136/esmoopen-2016-000111
Table 2 Univariate analysis of progression-free survival (PFS) and overall survival (OS) in patients receiving regorafenib
PFS OS
Category HR 95% CI Chi2 p Value HR 95% CI Chi2 p Value
Radiological 
predictors at 
baseline CECT
Cavitation No 1 - 4.948 0.03 1 - 7.320 0.007
Yes 0.50 0.27–0.92 0.23 0.08–0.66
Density of liver 
metastases
  Radiologist A
   μ (unit:10 HU) - 1.02 0.89–1.16 0.079 0.78 0.97 0.81–1.17 0.080 0.78
   σ (unit:10 HU) - 0.76 0.51–1.13 1.821 0.18 1.35 0.84–2.18 1.552 0.21
  Radiologist B
   μ (unit:10 HU) - 1.02 0.89–1.16 0.056 0.81 0.99 0.82–1.20 0.005 0.94
   σ (unit:10 HU) - 0.92 0.62–1.38 0.151 0.70 1.84 1.10–3.06 5.489 0.02
Sum of target 
lesions (unit: 1 cm)
- 0.99 0.96–1.02 0.394 0.53 1.05 1.02–1.09 9.964 0.002
Radiological 
predictors at 
week 8 CECT
Cavitation No 1 - 5.211 0.02 1 - 1.105 0.30
Yes 0.58 0.36–0.93 0.71 0.38–1.34
Density of liver 
metastases
  Radiologist A
   μ (unit:10 HU) - 0.91 0.81–1.01 3.178 0.07 0.94 0.82–1.07 0.946 0.33
   σ (unit:10 HU) - 1.01 0.90–1.13 0.009 0.92 0.90 0.78–1.03 2.346 0.13
  Radiologist B
   μ (unit:10 HU) - 0.94 0.83–1.06 0.965 0.33 0.99 0.86–1.15 0.011 0.91
   σ (unit:10 HU) - 0.95 0.85–1.07 0.784 0.38 0.98 0.85–1.14 0.049 0.82
ΔSTL (unit:10%) - - - - - 1.16 1.06–1.27 9.809 0.002
RECIST 1.1 PD - - - - 1 -
DCR - - - - 0.23 0.14–0.40 28.339 <0.001
Other predictors
Age (years) at 
random (unit: 10 
years)
- 1.01 0.83–1.22 0.003 0.96 0.87 0.66–1.14 0.975 0.32
Sex Male 1 - 6.749 0.009 1 - 3.702 0.05
Female 1.63 1.13–2.36 1.62 0.99–2.66
ECOG 0 1 - 1.665 0.20 1 - 5.801 0.02
1 1.28 0.88–1.85 1.83 1.12–2.98
KRAS mutation No 1 - 0.394 0.53 1 - 0.310 0.58
Yes 0.89 0.61–1.29 0.86 0.52–1.44
More than three 
lines before 
regorafenib
No 1 - 0.326 0.57 1 - 0.013 0.91
Yes 0.90 0.62–1.30 0.97 0.60–1.59
Time from M1 
diagnosis to 
randomisation 
(years)
- 0.90 0.78–1.03 2.552 0.11 0.92 0.76–1.10 0.873 0.35
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PFS OS
Category HR 95% CI Chi2 p Value HR 95% CI Chi2 p Value
Liver target lesions No 1 - 4.478 0.03 1 - 10.554 0.001
Yes 1.55 1.03–2.33 3.06 1.56–6.00
Lung target lesions No 1 - 0.350 0.55 1 - 0.915 0.34
Yes 0.89 0.61–1.30 0.78 0.46–1.30
CECT, contrast-enhanced computed tomography; ECOG, Eastern Cooperative Oncology Group;  HU, Hounsfield unit; RECIST, Response 
Evaluation Criteria in Solid Tumors; µ = tumour density in HU; σ = standard deviation; ΔSTL = change in the sum of the target lesions 
diameters. 
Table 2 Continued 
Figure 2 Kaplan-Meier estimates of progression-free survival (PFS) in patients treated with regorafenib. (A) PFS according to 
the presence of cavitation at week 8. (B) PFS according to the presence of baseline cavitation. (C) Subgroup analysis of PFS in 
patients with baseline cavitation, according to its increase at week 8. (D) Subgroup analysis of PFS in patients without baseline 
cavitation, according to its onset at week 8.
all metastatic lesions, including non-target metastases (<1 
cm), and only 66% of patients had measurable lesions, 
making it difficult to compare data from these two 
different studies. Since the occurrence of cavitation of 
lung metastases can be of clinical concern in terms of risk 
of pulmonary haemorrhage,21 25 we reviewed the occur-
rence of grade 3 and 4 pulmonary adverse events in our 
cohort based on matched reporting from the CORRECT 
Trial. In our study, among the 36 patients who had cavi-
tation of lung metastases, we found only one respiratory 
grade 4 adverse event (pulmonary embolism) that has 
been judged as not related to regorafenib.
Measurement of pretreatment and on-treatment 
tumour density of liver metastases has been widely 
investigated in solid tumour assessments.5 26 In xeno-
graft models, regorafenib led to an early reduction of 
tumour perfusion and vascularity, assessable by radio-
logical imaging.27–29 In our study, regorafenib induced 
a decrease in tumour density in most of the patients. 
However, neither a reduction of tumour density at week 8 
nor baseline values were useful for predicting outcomes. 
This finding is supported by a recent study in patients 
with gastrointestinal stromal tumours treated with rego-
rafenib, in which CHOI criteria, which include tumour 
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Figure 3 Kaplan-Meier estimates of overall survival in patients treated with regorafenib. (A) Survival according to change in 
the sum of the target lesion diameters (ΔSTL) (≥9% vs. <9%). (B) Survival according to the presence of baseline cavitation. 
(C) Survival according to Response Evaluation Criteria in Solid Tumors (RECIST) response. All patients achieved disease 
control rate (DCR) had stable disease (SD) as best response because no partial response (PR) or complete response (CR) were 
reported. PD, progressive disease.
density variation besides dimensional changes, had a less 
favourable concordance between PFS and OS prediction 
when compared with RECIST 1.1 or WHO criteria.30 
In mCRC patients treated with regorafenib, Lim et al 
found a tumour density decrease in most of cases, but 
the magnitude of change was not associated with clinical 
outcomes.24
Our study has several limitations. First, it is a post hoc 
analysis of patients enrolled in a prospective, placebo-con-
trolled phase III trial. A priori power statistical analysis 
was not performed and the number of patients evaluated 
limits the interpretation of the results.
Second, we found both baseline and week-8 cavitation 
are associated with a favourable outcome to regorafenib. 
Unfortunately, the imbalance of baseline cavitation 
between regorafenib and placebo group did not allow 
to evaluate clinical outcomes in patients treated with 
placebo. This hamper to clarify whether baseline cavita-
tion affects the natural history of disease regardless of 
treatment received. For this reason, the role of cavita-
tion as predictive rather than prognostic marker should 
be further investigated in larger series and across other 
studies. Third, density was assessed in the same liver metas-
tases identified in the CORRECT study. Morphological 
features such as the presence of necrotic area may have 
affected the analysis of density. Finally, since we included 
only patients that underwent the first post-treatment 
CECT, planned at week 8, we cannot rule out a selection 
bias by excluding patients with more aggressive or primary 
resistant tumours. It remains to be assessed how fast cavi-
tation occurs and if an earlier evaluation by CECT would 
be capable of capturing the same radiological signals of 
efficacy.
CONCLUSIONS
Our findings showed that an early radiological assess-
ment of tumoural response to regorafenib is useful 
for driving clinical decisions. RECIST 1.1 remains an 
adequate method to assess therapeutic response, being 
associated with OS. The evaluation of tumour size as a 
continuous variable, expressed as ΔSTL, supports contin-
uation of treatment in those patients achieving stable 
disease without any tumour shrinkage. Our data also indi-
cate that the evaluation of liver metastases density does 
not provide complementary information to traditional 
dimensional-based criteria. Conversely, we identify lung 
metastases cavitation as a novel imaging predictor of 
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favourable clinical outcome to regorafenib that deserves 
consideration.
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